0001709409-21-000003.txt : 20210527 0001709409-21-000003.hdr.sgml : 20210527 20210527165327 ACCESSION NUMBER: 0001709409-21-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210527 DATE AS OF CHANGE: 20210527 EFFECTIVENESS DATE: 20210527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allarity Therapeutics, Inc. CENTRAL INDEX KEY: 0001860657 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-400976 FILM NUMBER: 21973691 BUSINESS ADDRESS: STREET 1: 210 BROADWAY STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 401-426-4664 MAIL ADDRESS: STREET 1: 210 BROADWAY STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 D 1 primary_doc.xml X0708 D LIVE 0001860657 Allarity Therapeutics, Inc. 210 BROADWAY SUITE 201 CAMBRIDGE MA MASSACHUSETTS 02139 401-426-4664 DELAWARE None None Corporation true 2021 Steve Carchedi 210 Broadway Suite 201 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director President and CEO Jens Erik Knudsen 210 Broadway Suite 201 Cambridge MA MASSACHUSETTS 02139 Executive Officer Treasurer and CFO James G. Cullem 210 Broadway Suite 201 Cambridge MA MASSACHUSETTS 02139 Executive Officer Senior VP, Corporate Development and Secretary Biotechnology Decline to Disclose 06b false 2021-05-20 false true true true Series A Preferred Stock and Common Stock issuable upon the conversion of Series A Preferred Stock true Initial funding of $20 million is conditioned upon the completion of a share exchange asset acquisition with Allarity Therapeutics A/S and an effective registration statement 0 LifeSci Capital LLC 168404 None None 250 West 55th Street 34th Floor New York NY NEW YORK 10019 NY NEW YORK false 40000000 20000000 20000000 Total Offering Amount represents the aggregate conversion price of Series A Preferred Stock and aggregate exercise price of warrants to purchase Common Stock. false 1 1500000 0 This item 15 reflects the placement agent fee of 7.5% paid to LifeSci Capital LLC 0 false Allarity Therapeutics, Inc. /s/ Steve Carchedi Steve Carchedi Chief Executive Officer 2021-05-27